Abstract
Most diseases that cause blindness do so as a result of neovascularization. Angiogenesis is a complex process regulated in adult tissues by a large interacting network of molecules. In pathological conditions the checks and balances of the angiogenesis system go awry and endothelial cells of the microvasculature, proliferate, migrate, and form new but leaky vessels that invade the tissue. Hemorrhaging vessels cause edema and damage to surrounding tissues, particularly the retina. Microvascular lesions often cause severe retinal detachment and loss of vision. In this review, the value of an important endogenous anti angiogenic molecule, PEDF, is discussed in relationship to its ability to prevent retinal cell death and counter the abnormal vessel growth induced by VEGF in the eye. Its control of a neuroprotective and an antineovascular regulatory axis that determines cell fate, and its possible use in combination therapeutic strategies for ocular neovascular diseases are also reviewed.
Keywords: Angiogenesis, pigment epithelial derived factor, vascular endothelial derived factor, age related macular degeneration, diabetic retinopathy, microvascular lesions, retina
Current Molecular Medicine
Title: PEDF in Angiogenic Eye Diseases
Volume: 10 Issue: 3
Author(s): J. Tombran-Tink
Affiliation:
Keywords: Angiogenesis, pigment epithelial derived factor, vascular endothelial derived factor, age related macular degeneration, diabetic retinopathy, microvascular lesions, retina
Abstract: Most diseases that cause blindness do so as a result of neovascularization. Angiogenesis is a complex process regulated in adult tissues by a large interacting network of molecules. In pathological conditions the checks and balances of the angiogenesis system go awry and endothelial cells of the microvasculature, proliferate, migrate, and form new but leaky vessels that invade the tissue. Hemorrhaging vessels cause edema and damage to surrounding tissues, particularly the retina. Microvascular lesions often cause severe retinal detachment and loss of vision. In this review, the value of an important endogenous anti angiogenic molecule, PEDF, is discussed in relationship to its ability to prevent retinal cell death and counter the abnormal vessel growth induced by VEGF in the eye. Its control of a neuroprotective and an antineovascular regulatory axis that determines cell fate, and its possible use in combination therapeutic strategies for ocular neovascular diseases are also reviewed.
Export Options
About this article
Cite this article as:
Tombran-Tink J., PEDF in Angiogenic Eye Diseases, Current Molecular Medicine 2010; 10 (3) . https://dx.doi.org/10.2174/156652410791065336
DOI https://dx.doi.org/10.2174/156652410791065336 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Growth Factors in the Pathogenesis of Retinal Neurodegeneration in Diabetes Mellitus
Current Neuropharmacology Cerebral Vascular Aging: Extending the Concept of Pulse Wave Encephalopathy Through Capillaries to the Cerebral Veins
Current Aging Science AMPK as a New Attractive Therapeutic Target for Disease Prevention: The Role of Dietary Compounds AMPK and Disease Prevention
Current Drug Targets Adult Stem Cell Therapy for Acute Brain Injury in Children
CNS & Neurological Disorders - Drug Targets Pathophysiology of the Vascular Wall and its Relevance for Cerebrovascular Disorders in Aged Rodents
Current Neurovascular Research Anti-VEGF Compounds in the Treatment of Neovascular Age Related Macular Degeneration
Current Drug Targets Erythropoietin and Oxidative Stress
Current Neurovascular Research Inhibitors of Nitric Oxide Synthase: What's up and What's Next?
Current Enzyme Inhibition Drug Targeting of Estrogen Receptor Signaling in the Cardiovascular System: Preclinical and Clinical Studies
Current Medicinal Chemistry - Cardiovascular & Hematological Agents ANN Classification and Modified Otsu Labeling on Retinal Blood Vessels
Current Signal Transduction Therapy Aflibercept (VEGF-TRAP): The Next Anti-VEGF Drug
Inflammation & Allergy - Drug Targets (Discontinued) Vascular Damage in Impaired Glucose Tolerance: An Unappreciated Phenomenon?
Current Pharmaceutical Design Endothelial Remodelling and Intracellular Calcium Machinery
Current Molecular Medicine Endothelial Dysfunction and Atherosclerosis: Focus on Novel Therapeutic Approaches
Recent Patents on Cardiovascular Drug Discovery Blood Platelet Reactivity and its Pharmacological Modulation in (People with) Diabetes Mellitus
Current Pharmaceutical Design Role of Endothelin in Diabetic Retinopathy
Current Vascular Pharmacology The Central Role of Angiotensin I-Converting Enzyme in Vertebrate Pathophysiology
Current Topics in Medicinal Chemistry Diffusion of Macromolecule Through Retina After Experimental Branch Retinal Vein Occlusion and Estimate of Intraretinal Barrier
Current Drug Metabolism Anti-VEGF Drugs in Eye Diseases: Local Therapy with Potential Systemic Effects
Current Pharmaceutical Design The Role of Vascular Endothelial Growth Factor Gene as the Genetic Marker of Atherothrombotic Disorders and in the Gene Therapy of Coronary Artery Disease
Cardiovascular & Hematological Agents in Medicinal Chemistry